DelveInsight’s “Burns Market Insights, Epidemiology, and Market Forecast – 2034” report delivers an in-depth understanding of burns, historical and forecasted epidemiology, as well as the burns market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

 

Discover Key Insights into the Burns Market with DelveInsight’s In-Depth Report @ Burns Market Size

 

Key Takeaways from the Burns Market Report

• In October 2024:- SERDA BV- This study will examine the tolerability of a gel formulation of the enzyme SN514 in patients with burns suitable for enzymatic debridement. In a rising dose fashion by sequential cohort, concentrations of 0.1%, 0.2%, 0.4% and 0.8% will be tested. Groups of 3 will undergo daily debridement for up to 7 days. Extent of debridement and adverse signs and symptoms will be recorded daily. Dose escalation will stop if a dose level is found to be intolerable. Dose escalation may accelerate if a tested dose is entirely ineffective. There is no placebo control as all burn wounds require debridement.
• As per DeveInsight analysis, in 2023, the total incident cases of burn injuries were reported to be approximately 5.4 million cases, out of which nearly 1.8 million cases required medical treatment in the 7MM. These cases are expected to increase by 2034, driven by a surge in industrial accidents, household mishaps, and natural disasters.
• The number of hospitalized burn cases in the 7MM market is expected to increase at an effective CAGR of 0.54% during the study period, i.e. 2020–2034. The forecast period is expected to see a rise in these cases, propelled by heightened awareness of the critical need for timely and suitable treatment of burn injuries, which in turn motivates patients to seek medical care for such cases.
• In 2023, the US had the highest incident population of burn injuries that required medical treatment with nearly 671,128 cases followed by Japan with approximately 329,241 cases and the UK with 280,817 cases.
• Among the EU4 and the UK, the UK had the highest incident population of burn patients that require medical treatment accounting for approximately 280,817 cases, followed by France and Spain with nearly 204,506, and 145,510 cases respectively.
• According to DeveInsight analysis in the EU4 and the UK, the majority of burn injury cases taking treatment were males with approximately 540,480 cases and 341,627 female cases in 2023. This is accompanied by the fact that major burn injuries occur at workplaces due to various occupational hazards and exposures.
• Based on etiology-specific burn incident cases in the US, flame/fire was the foremost contributing cause for burn injuries accounting for approximately 41%, while chemical contact occupied the least share with nearly 3.5% in 2023. Anticipated increases in such cases are attributed to activities such as cooking, motor vehicle incidents, and outdoor pursuits like camping or bonfires.
• In 2023, the severity-specific incident cases were approximately 11,483; 759,667; 79,500; and 32,683 for first-degree, second-degree, third-degree, and unspecified, respectively in the EU4 and the UK.
• The leading Burns Companies such as MediWound Germany GmbH, Kaken Pharmaceutical Co., Ltd., Kerecis, Mallinckrodt Pharmaceuticals, Avita Medical, Vericel Corporation, KeraNetics, Integra LifeSciences Corporation, PolyNovo, Medline Industries, Anika Therapeutics, Inc., ACell, Inc., Amryt Pharma, CUTISS AG, Skingenix, RenovaCare, and others.
• Promising Burns Therapies such as PluroGel, SN514-066b, EHSG-KF, STSG, and others.

 

Stay ahead in the Burns Therapeutics Market with DelveInsight’s Strategic Report @ Burns Market Outlook

 

Burns Epidemiology Segmentation in the 7MM

• Incident cases of burn patients requiring treatment
• gender-specific incident cases of treated burn injuries
• etiology-specific incident cases of treated burn injuries
• severity-specific incident cases of treated burn injuries
• incident cases of hospitalized burn patients

 

Download the report to understand which factors are driving Burns epidemiology trends @ Burns Prevalence

 

Burns Marketed Drugs

• NexoBrid/KMW-1: MediWound Germany GmbH/Kaken Pharmaceutical

NexoBrid, a concentrate of proteolytic enzymes enriched in bromelain, is an easy-to-use, topically-applied product that removes eschar in 4 h without harming the surrounding healthy tissues. NexoBrid’s rapid and selective debridement alleviates the known risks associated with eschars, such as infection, eventual sepsis, wound deterioration, and consequential scarring. It allows physicians to reach an informed decision on further treatment at an earlier stage by direct visual assessment of the actual burn depth. Furthermore, it minimizes the burden associated with invasive surgical procedures, reduces the need for skin grafting and sacrifice of healthy tissue from donor sites on a patient’s body, and generally results in a more favorable overall long-term patient outcome NexoBrid is approved in over 40 countries including the United States, European Union, and Japan.

 

• Kerecis Omega3: Kerecis

Kerecis (formally known as Marigen) produces skin and tissue-based products for use in surgery and for treating wounds. Kerecis Omega3 is intact fish skin rich in naturally occurring Omega3 polyunsaturated fatty acids. The material, which is used to regenerate damaged human tissue, has the potential to accelerate healing. When grafted onto damaged human tissue such as a burn or a diabetic wound, the material recruits the body’s own cells and is ultimately converted into living tissue. Kerecis has a wide range of products for the treatment of burns that includes Kerecis Omega3 Wound, Kerecis Omega3 OR, Kerecis Omega3 MicroGraft, Kerecis Omega3 GraftGuide, and Kerecis Primary Wound Spray, some of which are approved and some are not. Kerecis products utilize multiple patented fatty-acid technologies to protect and regenerate tissue across two core technologies: Kerecis Omega3 Fish Skin and Kerecis Omega3 Viruxid.

 

• StrataGraft: Mallinckrodt Pharmaceuticals

StrataGraft is a viable, bioengineered, allogeneic, cellularized scaffold product derived from keratinocytes grown on gelled collagen-containing dermal fibroblasts. It is designed to deliver viable cells to support the body’s ability to heal and contains metabolically active cells that produce and secrete a variety of growth factors and cytokines. Growth factors and cytokines are known to be involved in wound repair and regeneration. The product is designed with both dermal and epidermal layers composed of well-characterized human cells. StrataGraft is intended to be applied in appropriate aseptic conditions, such as the operating room, and can be sutured, stapled, or secured with a tissue adhesive. In June 2021, the US FDA approved Mallinckrodt Pharmaceuticals StrataGraft (allogeneic cultured keratinocytes and dermal fibroblasts in murine collagen – dsat) for the treatment of adults with thermal burns containing intact dermal elements for which surgical intervention is clinically indicated (deep partial-thickness burns).

 

Burns Emerging Drugs

• MW-III: Skingenix

MW-III, a product by Skingenix, is a topical product being evaluated for second-degree burns in adult patients. The drug is a botanical drug product developed for treating burns and other cutaneous wounds, which will be made from natural ingredients such as Sesame Oil, Coptidis Rhizoma, Scutellariae Radix, Phellodendri Chinesis Cortex, Pheretima, formulated as an ointment with Beeswax.

 

• DenovoSkin (EHSG-KF): CUTISS AG

DenovoSkin being developed by CUTISS AG and others, is bio-engineered within large quantities (>1:100) with a thick, double-layer, robust structure. DenovoSkin is a patented, personalized, autologous bio-engineered human skin graft classified as an Advanced Therapy Medical Product (ATMP). DenovoSkin has completed Phase I in pediatric patients. The company is working towards bringing this promising treatment to patients suffering from severe burns and skin injuries and is also working on the scale-up of the production process using automation. The drug candidate is currently undergoing evaluation in two Phase II/III trials, and comprehensive data analysis, including a three-year follow-up, is expected to be available by 2025.

 

Get In-Depth Knowledge on Burns Market Trends and Forecasts with DelveInsight @ Burns Treatment Market

 

Burns Therapeutics Market

The treatment of burns involves various medications and ointments, such as Albumin human, Cinchocaine, Mafenide Acetate, Nitrofurazone, Silver Sulfadiazine, Sodium Hyaluronate, and Zinc oxide, among others. These are utilized to address shock, alleviate pain and itching, and prevent bacterial infections commonly associated with burn injuries. The current promising pharmacological classes for burns treatment include topical antimicrobial agents, analgesics, corticosteroids, NSAIDs, growth factors and cytokines, biological skin substitutes, and others.

 

 Burns Market Outlook

In the current market scenario, the standard treatment for skin burns involves medications, wound dressings, therapy, and surgery. The treatment goals are to control pain, remove dead tissue, prevent infection, reduce scarring risk, and regain function. The treatment depends on the severity of the burn.

Apart from the pharmacological treatment options, the most important management practice involves surgery. Early autografting then builds on these improvements by rapidly closing excised wounds, further reducing infection risk, decreasing pain, and enabling earlier mobilization. If there are concerns about the viability or bacterial load on the wound bed and/or the patient’s stability, allografting is preferred to cover the debrided wound temporarily.

 

Unlock Strategic Insights with DelveInsight’s Comprehensive Burns Market Report @ Burns Market Drivers and Barriers

 

Scope of the Burns Market Report

• Coverage- 7MM
• Burns Companies- MediWound Germany GmbH, Kaken Pharmaceutical Co., Ltd., Kerecis, Mallinckrodt Pharmaceuticals, Avita Medical, Vericel Corporation, KeraNetics, Integra LifeSciences Corporation, PolyNovo, Medline Industries, Anika Therapeutics, Inc., ACell, Inc., Amryt Pharma, CUTISS AG, Skingenix, RenovaCare, and others.
• Burns Therapies- PluroGel, SN514-066b, EHSG-KF, STSG, and others.
• Burns Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
• Burns Unmet Needs, KOL’s views, Analyst’s views, Burns Market Access and Reimbursement

 

Table of Content

1 Key Insights

2 Report Introduction

3 Burns Market Overview at a Glance

4 Methodology of Burns Epidemiology and Market

5 Executive Summary of Burns

6 Key Events

7 Disease Background and Overview of Burns

8 Patient Journey

9 Epidemiology and Patient Population

10 Marketed Drugs

11 Emerging Drugs

12 Burn: Market Analysis

13 Key Opinion Leaders’ Views

14 SWOT Analysis

15 Unmet Needs

16 Market Access and Reimbursement

17 Appendix

18 DelveInsight Capabilities

19 Disclaimer

20 About DelveInsight

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/